Flapping loops: roles for hinges in a ligand-binding domain of the nicotinic receptor

(A perspective for "Glycine hinges with opposing actions at the acetylcholine receptor-channel

transmitter binding site"

by Prasad Purohit and Anthony Auerbach)

Joe Henry Steinbach

Department of Anesthesiology

Washington University School of Medicine

660 S Euclid Ave

Saint Louis MO

63110

1

MOL #70102

running title: Glycine hinges modify gating

Joe Henry Steinbach

Department of Anesthesiology

Washington University School of Medicine

660 S Euclid Ave

Saint Louis MO

63110

Email: jhs@morpheus.wustl.edu

text pages: 6

tables: none

figures: 2

references: 18

Nonstandard abbreviations:

A: agonist molecule, R: receptor with a closed channel, R*: receptor with an open channel

Abstract

One of the goals of molecular pharmacology is to understand the machinery that converts information about the presence of a chemical (binding) to a functional consequence. Agonists are drugs which bind to their molecular targets and cause conformational changes underlying activation of the target. Inevitably, therefore, it can be difficult to disentangle the affinity of the agonist for the target from its efficacy in producing the ensuing conformational change. Efficacy depends on two factors: the intrinsic equilibrium between active and inactive states in the absence of agonist, and the energy contributed by the agonist due to the relative affinities of agonist for the active and inactive states. These difficulties are particularly frustrating when the goal is to determine the role(s) that particular residues in a target protein have in shaping the overall efficacy of a drug: how is it possible to unambiguously distinguish a role in determining intrinsic efficacy from one in determining relative affinity? This perspective highlights a research article in this issue (p.___) which demonstrates a quantitative approach to the resolution of this problem in the case of activation of the muscle nicotinic receptor. This elegant (if demanding) approach involves determining, separately, the consequences of specific mutations on gating in the unliganded and liganded states.

The evolution of our thinking about how drug effects are mediated received a strong impetus when Langley (Langley, 1905) proposed that nicotine combines with a specific receptive substance in striated muscle (see Figure 1A) and shortly afterwards Hill (Hill, 1909) derived a simple binding equation. However, further advances in understanding agonist activity were slow in coming. In 1956 Stephenson (Stephenson, 1956) introduced the concept that "affinity," the binding interaction between drug and target, and "efficacy," the ability of the drug to produce an effect, are separable. del Castillo and Katz (del Castillo and Katz, 1957) were the first to propose a specific kinetic scheme with separate steps for binding and activation (Figure 1B), again for the muscle nicotinic receptor to explain the nature of partial agonists. Subsequent work demonstrated that almost all of the active nicotinic receptors had 2 bound agonist molecules. The advent of high resolution single channel recordings then provided evidence that the receptors could be active, albeit rarely, when only a single agonist was bound (Colquhoun and Sakmann, 1985), or even in the absence of agonist (Jackson, 1984). At present the core activation scheme for the nicotinic receptor shows 6 major states for the receptor: open- or closed-channel conformations each with 3 degrees of ligation (Figure 1C). Other long-lived states have been identified, most prominently the desensitized state, but they can be separated out in single channel recordings so that this core activation process can be studied. It is also clear that the transition between closed and open states proceeds through a series of short-lived intermediate states (Auerbach, 2010), some of which have been detected in high resolution recordings (Lape et al., 2008; Mukhtasimova et al., 2009).

The scheme in Figure 1C is a two-conformation, concerted transition mechanism

(Changeux and Podleski, 1968; Monod et al., 1965; Wyman and Allen, 1951) in which the receptor can adopt two conformations - closed channel and open channel. The top row contains receptors with closed channels and corresponds to the low affinity conformation, with dissociation constant K_D. The bottom row shows receptors with open channels and corresponds to the high affinity conformation (dissociation constant J_D, with $J_D << K_D$). Channel opening is indicated by vertical transitions between the two rows. Agonists activate the receptor by binding more tightly to the receptor with an open channel, so increasing the proportion of receptors with open channels. There are 2 fundamental parameters in this scheme. The first is the opening equilibrium for the unliganded receptor, E_0, given by the ratio of the opening rate for the unliganded receptor to the closing rate ($R \leftrightarrow R^*$ in the figure). The second is the affinity for the closed state relative to that for the open state ($\lambda = K_D / J_D$). The efficacy for a diliganded receptor (E_2) is determined by both E_0 and λ ($E_2 = \lambda^2 E_0$). Accordingly, by determining E_0 and E_2 it is possible to calculate the ratio of affinities, λ.

The research in the article by Purohit and Auerbach (page ___) is on the muscle nicotinic receptor. A long series of studies has provided a strong quantitative picture of activation, and the analysis of a myriad of mutated residues (in conjunction with structural information) has given insights into the timing of conformational changes in different regions, the interactions among amino-acid side chains, and the basis for interactions between an agonist and the receptor. What the authors have done to extend this knowledge is to dissect the contribution of particular residues to two aspects of agonist efficacy: the relative binding affinities for the closed- and open-channel states, and the intrinsic efficacy for channel opening. The approach relies on the kinetic framework shown in Figure 1C.

The agonist-binding site in the nicotinic receptor is formed at the interface between two

subunits (see Figure 1 of Purohit and Auerbach). The α subunit contributes 3 "loops" (the A, B

and C loops) and the adjacent δ or ε subunit contributes 3 more. The α subunit B loop contains a

critical tryptophan residue (W149) which is involved in agonist binding, and has 2 glycine

residues, one at either end (G147 & G153). The question the authors address is whether

flexibility of the loop, associated with presence of the glycine "hinges" at the ends, is required

for normal function.

Purohit and Auerbach measured the opening equilibrium for the diliganded receptor (E_2)

and for the unliganded receptor (E_0), using single channel recordings. E_2 is (relatively)

straightforward: the channel opening rate is measured at a saturating concentration of agonist, the

closing rate at a low concentration, and the ratio computed. Measuring E_0 is more complicated,

because the value is extremely low (for wild-type receptors it is about 5×10^{-7}), and so events are

too rare to unambiguously characterize. (Values for E_0 have been estimated for other channels

and also are quite small; e.g. for the $GABA_A$ receptor $\sim 10^{-5}$ (Chang and Weiss, 1999) and for the

BK potassium channel $\sim 10^{-7}$ (Horrigan and Aldrich, 2002).) Purohit and Auerbach utilized a

subunit which contained a set of mutations which greatly increase the occurrence of unliganded

openings as the base construct. The effect of the additional mutation under study was then

compared to the base parameters. This approach relies on a demonstration that the effects of the

background mutations are independent (energetic contributions to activation are additive) among

themselves and with the test mutation (Jha and Auerbach, 2010; Purohit and Auerbach, 2009;

Purohit and Auerbach, 2010).

What is the answer? Mutations to the two glycines have opposite effects on the efficacy of gating for diliganded receptors, by affecting different parameters (see Figure 2). Mutations to G147 decrease E_0, by decreasing the opening rate and increasing the closing rate. In contrast, mutations to G153 increase E_0, by increasing the opening rate and somewhat slowing the closing rate. The consequences for the relative affinities are different. In this case, mutations to G147 greatly decrease λ, while mutations to G153 decrease λ only slightly. The overall effect is that the mutations to G147 greatly decrease the efficacy of gating for diliganded receptors (E_2 decreases more than 1000-fold) while mutations to G153 increase E_2 by 10- to 60-fold. The authors also measured the affinity for the resting receptor for selected mutations. The affinity was decreased by the mutation G147S (K_D increased), and increased by 3 mutations at G153. Clearly, these "hinges" are significant determinants of overall receptor function. Flexibility at G147 seems to be critical for positioning residues in the binding site for optimal interaction with the agonist, both for the resting receptor and even more so for the open-channel receptor. In contrast, flexibility at G153 seems to be more important for governing the efficacy of gating. As the authors put it, G147 is an "activation hinge" while G153 is a "deactivation hinge."

Mutations to the binding residue, W149, consistently reduce λ (Figure 2) and have rather variable effects on E_0. These results indicate the importance of W149 in interacting with the agonist, particularly in the open state of the receptor. The effects on E_0 are an indication that structural changes in the ligand-binding domain (unsurprisingly) affect the overall conformational stability of the receptor.

Loop B has not been previously studied in terms of conformational flexibility. Attention has been focused on Loop C, as X-ray crystallographic studies of the related ACh-binding protein indicated that loop C closes down on bound agonists (Celie et al., 2004), and studies of mutated subunits support the idea that this closure is functionally important (Mukhtasimova et al., 2009). The present work demonstrates that conformational flexibility in other parts of the binding site is critical for normal function of the receptor.

It is interesting to note that much larger changes occurred in the rate for entering the diliganded open state than in leaving the diliganded open state. This seems perhaps unintuitive, given that the high-affinity (open) conformation is expected to be stabilized by binding. The explanation likely lies in the rapid, largely unresolved transitions between states that the receptor makes as it opens (Auerbach, 2010). Perhaps the stabilizing energy contributed by agonist binding to the high-affinity form of the receptor increases the likelihood that the receptor will be in states further along the opening transition pathway, but before the final step for opening. This would agree with the observations that activation by agonists with different efficacies results in similar rates for leaving the diliganded open state, but very different rates for entering it. Previous workers have also concluded that the major determinants of efficacy lie in transitions preceeding actual channel opening (Lape et al., 2008; Mukhtasimova et al., 2009). One physical interpretation is that the increase in affinity reflects closure of the agonist-binding site (Mukhtasimova et al., 2009). In this case, it seems that flexibility in Loop B is critical, as well as movement of Loop C.

This work sets a standard for examining structure-activity relationships for activation of

proteins by drugs. It builds on a broad data-base and requires the precision of single-protein

kinetics, as well as the demonstration that a particular kinetic scheme is appropriate for analysis.

The power of this approach is also a limitation: it requires the quantitative validation of the

kinetic scheme applied and extremely high-quality data with high time resolution. The lessons

learned will be valuable in interpreting data from other, less complete studies and will definitely

be applicable to understanding the other members of the nicotinic receptor gene family.

Acknowledgments

Authorship Contribution

Wrote or conributed to the writing of the manuscript: Steinbach

Other (read the MS and interpreted the results): Steinbach

References

Auerbach A (2010) The gating isomerization of neuromuscular acetylcholine receptors. *J Physiol* **588**:573-586.

Celie PH, van Rossum-Fikkert SE, van Dijk WJ, Brejc K, Smit AB and Sixma TK (2004) Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. *Neuron* **41**:907-914.

Chang Y and Weiss DS (1999) Allosteric activation mechanism of the α1β2γ2 γ-aminobutyric acid type A receptor revealed by mutation of the conserved M2 leucine. *Biophys J* **77**:2542-2551.

Changeux JP and Podleski TR (1968) On the excitability and cooperativity of the electroplax membrane. *Proc Natl Acad Sci U S A* **59**:944-950.

Colquhoun D and Sakmann B (1985) Fast events in single-channel currents activated by acetylcholine and its analogues at the frog muscle end-plate. *J Physiol (Lond)* **369**:501-557.

del Castillo J and Katz B (1957) Interaction at end-plate receptors between different choline derivatives. *Proc R Soc Lond B Biol Sci* **146**:369-381.

Hill AV (1909) The mode of action of nicotine and curari, determined by the form of the contraction curve and the method of temperature coefficients. *J Physiol* **39**:361-373.

Horrigan FT and Aldrich RW (2002) Coupling between voltage sensor activation, Ca^{2+} binding and channel opening in large conductance (BK) potassium channels. *J Gen Physiol* **120**:267-305.

Jackson MB (1984) Spontaneous openings of the acetylcholine receptor channel. *Proc Natl Acad Sci U S A* **81**:3901-3904.

Jha A and Auerbach A (2010) Acetylcholine receptor channels activated by a single agonist molecule. *Biophys J* **98**:1840-1846.

Langley JN (1905) On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. *J Physiol* **33**:374-413.

Lape R, Colquhoun D and Sivilotti LG (2008) On the nature of partial agonism in the nicotinic receptor superfamily. *Nature* **454**:722-727.

Monod J, Wyman J and Changuex J-P (1965) On the nature of allosteric transitions: A plausible model. *J Mol Biol* **12**:88-118.

Mukhtasimova N, Lee WY, Wang HL and Sine SM (2009) Detection and trapping of intermediate states priming nicotinic receptor channel opening. *Nature* **459**:451-454.

Purohit P and Auerbach A (2009) Unliganded gating of acetylcholine receptor channels. *Proc Natl Acad Sci U S A* **106**:115-120.

Purohit P and Auerbach A (2010) Energetics of gating at the apo-acetylcholine receptor transmitter binding site. *J Gen Physiol* **135**:321-331.

Stephenson RP (1956) A modification of receptor theory. *Br J Pharmacol Chemother* **11**:379-393.

Wyman J and Allen DW (1951) The problem of the heme interactions with hemoglobin and the basis of the Bohr effect. *J Polym SciB* **7**:499-518.

Legends for figures

Figure 1. Kinetic models for agonist activation of the nicotinic receptor. Panel A shows the

initial concept that an agonist (A) binds to a receptor (R), to produce an active complex (AR*;

Langley, 1905; Hill, 1909). Panel B shows the extension proposed by del Castillo and Katz

(1957), in which binding and activation are separated into two steps. Panel C shows the current

scheme for the "core" activation process for the nicotinic receptor. There are two functional

states for the receptor, that with a closed channel (boxed top row) with dissociation constant K_D

and that with an open channel (bottom row) with dissociation constant J_D ($J_D \ll K_D$). Each

functional state has three degrees of ligation with agonist, and the two binding steps for each

functional form have the same microscopic affinities (they are independent and identical) (c.f.

Jha and Auerbach, 2010). Channel opening involves movement from the top row to the bottom

row. Even in the absence of bound agonist (left-most column, R $\leftrightarrow$ R*) opening can occur with

an equilibrium open constant given by E_0 (E_0 = opening rate/closing rate). The fundamental

parameters for the two-conformation, concerted transition model are shown. The first is the ratio

of the dissociation constants for the closed (low affinity) state to that for the open (high affinity)

state ($\lambda = K_D/J_D \gg 1$). The second is the intrinsic opening equilibrium for the unliganded

receptor (E_0). The opening equilibrium for the doubly-liganded receptor (A$_2$R $\leftrightarrow$ A$_2$R*; E_2 =

$\lambda^2 E_0$) is much larger than for the unliganded receptor.

Figure 2. Effects of mutations to the glycine "hinges" on kinetic parameters. The changes

produced by mutations in parameters for activation are shown as the ratio of the values in the

mutated receptor to the wild-type. Note that the ratios are plotted on a logarithmic scale, as the

total range in ratios is about 10^7. The left panel shows relative values for the equilibrium

parameters E_0, λ and E_2 ($E_2 = E_0\lambda^2$). The right panel shows effects on rates (f0 is the rate for

entering the unliganded open state, b0 the rate for leaving the unliganded open state, and f2 and

b2 are the rates for the diliganded state). A change in E_2 ($E_2 = f2/b2$) is largely determined by the

change in f2. Values obtained from the supplementary data in Purohit and Auerbach.

A   A + R ⇌ AR*   **Binding is activation**

―――――――――――

B   closed A + R ⇌ AR   **Binding & activation**

                              ↑↓

         open   AR*

―――――――――――

C   closed [A + R ⇌ AR ⇌ A_2R]   low affinity: K_D

         E_0 ↑↓   ↑↓   ↑↓ E_2 $\lambda = K_D / J_D$

         open   [A + R* ⇌ AR* ⇌ A_2R^*]   high affinity: J_D

              low   high
              gating   gating
              E_0 $E_2 = E_0 \lambda^2$

Figure 1

Figure 2